Evaluation of the Analgesic Effect of Direct Current Stimulation in the Treatment of Pelvic Pain,… (NCT07237165) | Clinical Trial Compass
Not Yet RecruitingNot Applicable
Evaluation of the Analgesic Effect of Direct Current Stimulation in the Treatment of Pelvic Pain, Comparing Three Groups: Trans-spinal Stimulation, Ganglionic Stimulation, and Placebo. A Randomized Double-blind Study
France60 participantsStarted 2025-12-01
Plain-language summary
The purpose of this study is to evaluate the analgesic effectiveness of direct current stimulation (tsDCS) in the treatment of pelvic pain by comparing three groups:
* Trans-spinal tsDCS stimulation,
* Ganglionic tsDCS stimulation,
* Placebo (sham) tsDCS stimulation.
Who can participate
Age range18 Years – 85 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* Patient aged 18 to 85 years, suffering from pelvic pain for more than one year (excluding musculoskeletal causes).
* Patient with stable ongoing medication (analgesic or otherwise) for at least one month.
* Patient for whom lack of response to conventional treatments has led the pain specialist or referring physician to consider non-pharmacological therapeutic options.
* Patient reporting a pain intensity score \>3 on the Numeric Visual Pain Scale (NVPS) during pre-screening.
* Patient affiliated with the national health insurance system or an equivalent scheme.
* Patient who has provided written informed consent.
Exclusion Criteria:
* History of drug addiction.
* History of psychiatric disorders likely to interfere with the proper conduct of the study.
* Patient with skin lesions in the lumbar region.
* Person unable to understand the study protocol.
* Individuals covered by Articles L1121-5 to L1121-8 of the French Public Health Code, corresponding to all protected persons: pregnant women, women in labor, breastfeeding mothers, individuals deprived of liberty by judicial or administrative decision, or under legal protection.
* Subject currently in the exclusion period of another clinical trial
What they're measuring
1
Evolution of Pain
Timeframe: Pain progression will be assessed from week 1 (before treatment) to week 7 (end of treatment)